Evan Hall

Med onc at UW/SCCA/Fred Hutch focused on melanoma and RCC, interested in patient/caregiver QOL and all things immunotherapy. All opinions are my own.

[Stephanie Harman @Steph_HarmanMD]

Fantastic @StanfordDeptMed Grand Rounds now for the memorial @BGabster lecture

@DianaCejasMD presents on writing and illness. & some basic neuroanatomy for us internists

A special gathering for our community. Our gratitude to Dr. Gabster’s family.
https://t.co/8Mq9ACR51D

[Allison Betof, MD, PhD, FASCO @DrBetofMDPhD]

The Phase 2/3 Randomized trial of RP2+nivolumab for #uveal #melanoma is now OPEN at @StanfordCancer. This is for patients who have not had prior checkpoint inhibitors or liver-directed therapy. Prior tebentafusp is allowed. The phase 1 data were quite promising and we're excited to be able to offer this to our patients!

[Simon Lo @SimonLo21054188]

Representing ⁦@fredhutch⁩ ⁦@UWMedicine⁩ ⁦@uwsomwwami⁩ Kidney Cancer Multidisciplinary Team #IKCSNA2024 @KidneyCancer ⁦@spsutkaMD⁩

[Janice Mehnert, MD @JaniceM10]

Nice to see this out there! Dr. Silk did a heroic job leading this trial of tvec and nivolumab in rare skin cancers. A collaboration that has spanned many institutions! ⁦@Perlmutter_CC⁩ ⁦@DanaFarber⁩ ⁦@theNCI⁩ ⁦@RutgersCancer⁩

[Petros Grivas @PGrivasMDPhD]

Fantastic work @LisaTachiki @BhatiaS_MD @fredhutch et al.

@FredHutchGO @HutchPresident @nicoleflemingmd @JessicaHawleyMD @RahulBanerjeeMD @EvanHallMD @btfoundation @binayshah @MonikaJoshimd @UWMedicine @AJPortuguese @HannahRAbrams @natashakwemd @valdesan @OncoAlert @sitcancer

[Journal for ImmunoTherapy of Cancer @jitcancer]

New #JITC article: Intratumoral STING agonist reverses immune evasion in PD-(L)1-refractory Merkel cell carcinoma: mechanistic insights from detailed biomarker analyses https://t.co/nOqLOMlBoU @BhatiaS_MD @PaulNghiem

[Evan Hall @EvanHallMD]

Very thoughtfully designed study. Good rationale to reduce intensity of lymphodepletion. TIL can produce intracranial responses in some patients! Clearly, some pts have explosive disease kinetics and cannot wait (even w bridging) for this approach, but good to have pilot data 2/

[Evan Hall @EvanHallMD]

@DrBetofMDPhD @StanfordCancer presents on TIL for patients with untreated brain metastases post PD-1 at #SMR24. Very important area to generate data. Time for TIL process, need for anesthesia/harvest, chemotherapy causing ⬇️plts, IL-2 etc complicate this scenario. 1/

[Simon Lo @SimonLo21054188]

Very proud to be part of multidisciplinary kidney cancer clinic ⁦@fredhutch⁩ providing 1 stop service for kidney cancer patients⁦@spsutkaMD⁩ ⁦@DanLinMD⁩ ⁦@schadegr⁩ ⁦@EvanHallMD⁩ ⁦@LisaTachiki⁩ ⁦@WinstonVuong⁩ ⁦@MartinMaMDPhD⁩

[Pauline Funchain @FunchainMD]

Find yourself doctors (and colleagues) that get excited about moving the field forward like @alexshoushtari and @DrBetofMDPhD

Reunion of kindred spirits this morning at Living with Melanoma @AIMatMelanoma and @StanfordCancer

[Dr Julia Lai-Kwon @JuliaLaiKwon]

Are you interested in how to select side-effects for ePRO symptom monitoring ?

We conducted a national modified Delphi to do just that for #immunotherapy side-effects in routine care and found limited coverage of clinically relevant side-effects by existing PROMs @JCOOP_ASCO

[Petros Grivas @PGrivasMDPhD]

Excited to present @ASCO highlights in GU cancers in @ScrippsHealth in Seattle! So much great data to cover! @fredhutch @shilpaonc @Uromigos @urotoday @OncoAlert @valdesan @EvanHallMD @BhatiaS_MD @JessicaHawleyMD @RahulBanerjeeMD @montypal @neerajaiims @jrgralow @TiansterZhang

[Evan Hall @EvanHallMD]

@HanZhuMD @nih_nhlbi @NIH @StanfordCVI @StanfordDeptMed @Joseph_C_Wu @SeanM_Wu @EldrinL Congrats Han!!

[A Cure In Sight @ACureInSight1]

That Seattle 5k was fantastic! 🤩

We had 122 people race for a cure with us! Thank you to each and every one of you! We are so appreciative of all of your support! 🥇

We were able to raise over $10,000! 👏 👏 👏

And we'd like to thank @fredhutch for sponsoring this event!

[Mark Lewis, MD, FASCO @marklewismd]

Heard this today at a funeral and it hit me like a ton of bricks

[Mark Lewis, MD, FASCO @marklewismd]

I don’t know who else needs to hear this, but I know I did

[Dr Julia Lai-Kwon @JuliaLaiKwon]

Check out our latest paper on the development of the new @EORTC_QLG advanced #melanoma module.

Great to contribute 🇦🇺 perspectives from @MelanomaAus. @PeterMacCC patients will also be included in Phase 3. #melsm

https://t.co/j14hwoL5h5

[Dr Julia Lai-Kwon @JuliaLaiKwon]

Great to see patient-reported outcomes (#PROs) 🔦at #ASCO24 across symptom science/ pall care + quality of care/ HSR tracks, incl as part of stepped models of care and in large real-world studies 👏👏.

Here are my #ASCO24 PRO highlights:

[Mark Lewis, MD, FASCO @marklewismd]

As the sun sets on #asco24 I’d be remiss not to say that I’m worried about my colleagues

I worry we are crushing one another with colossal expectations, with our emails & CVs

You are more than your publications & presentations

Please don’t tie your self-worth to brass rings

[Afreen Shariff, MD @afreenshariffmd]

#irAE outcomes needs to be right next to Progression free survival and Disease free survival as a core outcome.

Thank you @jillfeldman4 @thenasheffect @EladSharonMD @FunchainMD for amplifying this message.

#ASCO24